Asset Details
Do you wish to reserve the book?
Erlotinib-Associated Rash in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer Treated in the EURTAC Trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Erlotinib-Associated Rash in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer Treated in the EURTAC Trial
Do you wish to request the book?
Erlotinib-Associated Rash in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer Treated in the EURTAC Trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Erlotinib-Associated Rash in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer Treated in the EURTAC Trial
2015
Overview
This analysis investigates incidence and time course of rash in the EURTAC study.
Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy.
Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment.
Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.
Publisher
Future Medicine Ltd
Subject
Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Carcinoma, Non-Small-Cell Lung - complications
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - genetics
/ Carcinoma, Non-Small-Cell Lung - mortality
/ Complications and side effects
/ Exanthema - prevention & control
/ Humans
/ Lung Neoplasms - complications
/ Lung Neoplasms - drug therapy
/ Mutation
/ Protein Kinase Inhibitors - administration & dosage
/ Protein Kinase Inhibitors - adverse effects
/ Quinazolines - administration & dosage
/ Quinazolines - adverse effects
/ Rash
